China Resources Pharmaceutical announces leadership changes, dividend, mixed H1 2025 results

Effective August 26, 2025, Tao Ran resigned as an executive director, while Cheng Jie was appointed as an executive director, president, and a member of both the executive and corporate governance committees. Concurrently, Deng Rong resigned from the corporate governance committee. Following these changes, China Resources Pharmaceutical now complies with code provision C.2.1 regarding the separation of chairman and chief executive officer roles. Cheng Jie will not receive a director's emolument but is entitled to a pre-tax basic monthly salary of RMB84,000.

For the six months ended June 30, 2025, the Group reported total revenue of RMB131,866.8 million, a 2.5% increase year-on-year. Gross profit reached RMB21,509.6 million, up 2.8%, with an overall gross profit margin of 16.3%. However, net profit decreased by 8.8% to RMB5,053.6 million, and profit attributable to owners of the company fell by 20.3% to RMB2,077.3 million, with basic earnings per share at RMB0.33.

The board declared an interim dividend of RMB0.072 per ordinary share for the six months ended June 30, 2025, totaling RMB452 million. This dividend will be distributed on October 31, 2025, to shareholders registered by September 16, 2025, with an option to receive it in HKD at HKD0.0789 per share. The register of members will be closed from September 15-16, 2025.